Achieve Life Sciences announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,459,328 covering the mesylate salt formulation of cytisinicline and the process for its development. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. Achieve continues to pursue numerous patents that will further enhance the product’s stability and the potential for life cycle expansion via varying methods of administration. Achieve is currently conducting the final FDA-registration enabling Phase 3 ORCA-3 trial for smoking cessation and the Phase 2 ORCA-V1 trial evaluating cytisinicline for e-cigarette cessation. The Company continues to expect topline data results for both trials to be announced in the second quarter of 2023.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ACHV:
- Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
- Achieve Life Sciences reports Q3 EPS ($1.35), consensus ($1.13)
- Achieve Life achieves early completion of target enrollment in ORCA-V1 trial
- Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022